These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
508 related articles for article (PubMed ID: 24002278)
1. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A; JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278 [TBL] [Abstract][Full Text] [Related]
2. Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk. Lafeber M; Spiering W; Visseren FL; Grobbee DE; Bots ML; Stanton A; Patel A; Prabhakaran D; Webster R; Thom S; Rodgers A; Eur J Prev Cardiol; 2017 Jun; 24(9):951-961. PubMed ID: 28436727 [TBL] [Abstract][Full Text] [Related]
3. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care. Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A BMJ; 2014 May; 348():g3318. PubMed ID: 24868083 [TBL] [Abstract][Full Text] [Related]
4. A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk. Patel A; Cass A; Peiris D; Usherwood T; Brown A; Jan S; Neal B; Hillis GS; Rafter N; Tonkin A; Webster R; Billot L; Bompoint S; Burch C; Burke H; Hayman N; Molanus B; Reid CM; Shiel L; Togni S; Rodgers A; Eur J Prev Cardiol; 2015 Jul; 22(7):920-30. PubMed ID: 24676715 [TBL] [Abstract][Full Text] [Related]
5. Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular diseases. Bahiru E; de Cates AN; Farr MR; Jarvis MC; Palla M; Rees K; Ebrahim S; Huffman MD Cochrane Database Syst Rev; 2017 Mar; 3(3):CD009868. PubMed ID: 28263370 [TBL] [Abstract][Full Text] [Related]
6. Fixed-dose combination therapy for the prevention of cardiovascular disease. de Cates AN; Farr MR; Wright N; Jarvis MC; Rees K; Ebrahim S; Huffman MD Cochrane Database Syst Rev; 2014 Apr; 4(4):CD009868. PubMed ID: 24737108 [TBL] [Abstract][Full Text] [Related]
7. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease. Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A; Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587 [TBL] [Abstract][Full Text] [Related]
8. Polypill with or without Aspirin in Persons without Cardiovascular Disease. Yusuf S; Joseph P; Dans A; Gao P; Teo K; Xavier D; López-Jaramillo P; Yusoff K; Santoso A; Gamra H; Talukder S; Christou C; Girish P; Yeates K; Xavier F; Dagenais G; Rocha C; McCready T; Tyrwhitt J; Bosch J; Pais P; N Engl J Med; 2021 Jan; 384(3):216-228. PubMed ID: 33186492 [TBL] [Abstract][Full Text] [Related]
9. The evening versus morning polypill utilization study: the TEMPUS rationale and design. Lafeber M; Grobbee DE; Bots ML; Thom S; Webster R; Rodgers A; Visseren FL; Spiering W Eur J Prev Cardiol; 2014 Apr; 21(4):425-33. PubMed ID: 23382539 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Roshandel G; Khoshnia M; Poustchi H; Hemming K; Kamangar F; Gharavi A; Ostovaneh MR; Nateghi A; Majed M; Navabakhsh B; Merat S; Pourshams A; Nalini M; Malekzadeh F; Sadeghi M; Mohammadifard N; Sarrafzadegan N; Naemi-Tabiei M; Fazel A; Brennan P; Etemadi A; Boffetta P; Thomas N; Marshall T; Cheng KK; Malekzadeh R Lancet; 2019 Aug; 394(10199):672-683. PubMed ID: 31448738 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of a fixed dose combination (polypill) in secondary prevention of cardiovascular diseases in India: Within-trial cost-effectiveness analysis of the UMPIRE trial. Singh K; Crossan C; Laba TL; Roy A; Hayes A; Salam A; Jan S; Lord J; Tandon N; Rodgers A; Patel A; Thom S; Prabhakaran D Int J Cardiol; 2018 Jul; 262():71-78. PubMed ID: 29622506 [TBL] [Abstract][Full Text] [Related]
12. Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. Yusuf S; Pais P; Sigamani A; Xavier D; Afzal R; Gao P; Teo KK Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):463-71. PubMed ID: 22787067 [TBL] [Abstract][Full Text] [Related]
13. Comparison of a morning polypill, evening polypill and individual pills on LDL-cholesterol, ambulatory blood pressure and adherence in high-risk patients; a randomized crossover trial. Lafeber M; Grobbee DE; Schrover IM; Thom S; Webster R; Rodgers A; Visseren FL; Bots ML; Spiering W Int J Cardiol; 2015 Feb; 181():193-9. PubMed ID: 25528311 [TBL] [Abstract][Full Text] [Related]
14. ANICHKOV study: the effect of combined hypotensive and lipid-lowering therapy on cardiovascular complications in patients of high and very high risk. Sergienko IV; Ansheles AA; Drapkina ОМ; Gornyakova NB; Zubareva MY; Shepel RN; Kuharchuk VV; Boytsov SA Ter Arkh; 2019 May; 91(4):90-98. PubMed ID: 31094482 [TBL] [Abstract][Full Text] [Related]
15. Effect of Patient Financial Incentives on Statin Adherence and Lipid Control: A Randomized Clinical Trial. Barankay I; Reese PP; Putt ME; Russell LB; Loewenstein G; Pagnotti D; Yan J; Zhu J; McGilloway R; Brennan T; Finnerty D; Hoffer K; Chadha S; Volpp KG JAMA Netw Open; 2020 Oct; 3(10):e2019429. PubMed ID: 33034639 [TBL] [Abstract][Full Text] [Related]
16. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial. ; Yusuf S; Pais P; Afzal R; Xavier D; Teo K; Eikelboom J; Sigamani A; Mohan V; Gupta R; Thomas N Lancet; 2009 Apr; 373(9672):1341-51. PubMed ID: 19339045 [TBL] [Abstract][Full Text] [Related]
17. A Polypill for primary prevention of cardiovascular disease: a feasibility study of the World Health Organization. Soliman EZ; Mendis S; Dissanayake WP; Somasundaram NP; Gunaratne PS; Jayasingne IK; Furberg CD Trials; 2011 Jan; 12():3. PubMed ID: 21205325 [TBL] [Abstract][Full Text] [Related]
18. Effect of a Collaborative Care Model on Depressive Symptoms and Glycated Hemoglobin, Blood Pressure, and Serum Cholesterol Among Patients With Depression and Diabetes in India: The INDEPENDENT Randomized Clinical Trial. Ali MK; Chwastiak L; Poongothai S; Emmert-Fees KMF; Patel SA; Anjana RM; Sagar R; Shankar R; Sridhar GR; Kosuri M; Sosale AR; Sosale B; Rao D; Tandon N; Narayan KMV; Mohan V; JAMA; 2020 Aug; 324(7):651-662. PubMed ID: 32809002 [TBL] [Abstract][Full Text] [Related]
19. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. Lee JK; Grace KA; Taylor AJ JAMA; 2006 Dec; 296(21):2563-71. PubMed ID: 17101639 [TBL] [Abstract][Full Text] [Related]
20. Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial. Mariani J; Rosende A; De Abreu M; Gonzalez Villa Monte G; D'Imperio H; Antonietti L; Lemonnier G; de Bonis A; Tajer C Ther Adv Cardiovasc Dis; 2020; 14():1753944720912071. PubMed ID: 32186246 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]